A Phase 1/2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Glutaminase Inhibitor CB-839 in Combination with Nivolumab in Patients with Clear Cell Renal Cell Carcinoma and Other Solid Tumors
|Calithera Bioscienes, Inc.
|Male and Female Patients
|U.S. Govt. ID:
|Research Nurse Navigator: 212-342-5162 / email@example.com
The purpose of this trial is to evaluate the safety of CB-839 in combination with nivolumab for patients with advanced/metastatic clear cell Renal Cell Carcinoma (ccRCC), melanoma, and Non-Small Cell Lung Cancer. CB-839 is a drug designed to stop cancer growth by blocking glutaminase activity. Glutaminase is an enzyme in the body that is overproduced by some cancers and can fuel cancer growth. Nivolumab is a drug that makes cancer cells more vulnerable to attack by working with your bodys own immune system.
This study is closed
Gary Schwartz, MD
|Do you have melanoma?
|Have you received a prior immunotherapy for your melanoma?
|Did your disease get worse while you were on the immunotherapy?
|Do you need to take a steroid greater than 10mg a day?